Research programme: ion channel therapeutics - Abilita Bio

Drug Profile

Research programme: ion channel therapeutics - Abilita Bio

Alternative Names: Ion channel therapeutics - Ab7; Ion channel therapeutics - Ab8

Latest Information Update: 27 Sep 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Abilita Bio
  • Class Antibodies
  • Mechanism of Action Ion channel modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes
  • Available For Licensing Yes - Unspecified

Highest Development Phases

  • Research Unspecified

Most Recent Events

  • 22 Sep 2016 Research programme: ion channel therapeutics - Abilita Bio is available for licensing as of 22 Sep 2016.
  • 20 Sep 2016 Early research in Undefined indication (unspecified route)
  • 20 Sep 2016 Abilita Bio enters into a multi-target proof of concept agreement with an undisclosed global pharmaceutical company
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top